GlobeNewswire

NRT Technology Completes Acquisition of VisuaLimits, One of the Fastest Growing Gaming Supplier Companies in the US

Dela

Acquisition of VisuaLimits Strengthens NRT's Ability to Connect the Guest Experience(TM) Across the Entire Casino Resort

LAS VEGAS, Sept. 26, 2017 (GLOBE NEWSWIRE) -- NRT Technologies, Inc.,  a wholly-owned subsidiary of NRT Technology Corp. (together, "NRT") today announced the successful completion of its acquisition of VisuaLimits, LLC ("VL").   On September 20 2017, NRT and Sightline Payments announced an agreement to merge, with the combined entity to be called NRT Sightline (the "Transaction").  Following close of the Transaction, which remains subject to gaming regulatory approvals, Sightline's CEO and Founder, Kirk Sanford, will assume the role of CEO of NRT Sightline. NRT's current Founder, President and CEO, John Dominelli, will become Chairman of NRT Sightline and will remain active in leading the overall company strategy with a keen focus on driving the technology roadmap.

The acquisition of VL complements NRT's innovative and expansive payment product vision for casinos, which now includes VL's unique 12-in-1 solution.

The VL-Focus and VL-Flex, with their highly adaptive hardware and software, delivers a multitude of services to casino operators and patrons alike, including cashless payments through integration with Sightline's Play+, an HD display for gaming, TV, sports score and advertising messaging, dealer performance (automated hands per hour) and game utilization (automated headcounts), labor savings with time and attendance through Kronos integration, sophisticated surveillance, and 2-way communication functionality which allows dealers to easily contact security, place food and drink orders, and make dinner or club reservation for players.  And because casino operators can easily integrate VL platforms into their existing table rating system, VL offers the added benefit of eliminating the clutter and extra price of redundant hardware. Casino operators can often realize their ROI on VL-Focus and VL-Flex purchases in less than 3 months.

VL's newest product, the VL-EYE, interfaces with the VL-Focus to provide a full surveillance system, including facial, chip, and card recognition capabilities.  Casinos are lining up to be beta sites prior to the VL-EYE's launch next month at G2E. 

"Just in the last year alone VL has tripled its installed base and will finish this year with over 4000 'intelligent' VL-Focus devices, adding some well recognized names to its roster of casino customers, including 8 of the top 10 Global casino operators," said Dominelli.  "And we couldn't be happier with the people that will be joining NRT as part of this acquisition.  They bring a real passion and unparalleled expertise to our organization that will truly enable NRT to Connect the Guest Experience across the entire casino resort."

"The VL platform is like nothing else out there. We deliver actionable insights to operators, delivering tangible business improvements, transactional lift from payments, automated workflows, operational performance improvements and dynamic regulatory compliance. And operators love VL because our solutions consolidate the typical array of table games hardware to de-clutter and improve the overall 'look and feel' of gaming tables," said Ryan McClellan, VL's Co-Founder and former COO who now takes on the role of  SVP Table Game Solutions for NRT.   

"We have received such overwhelmingly positive feedback from operators about the VL product and this, coupled with the excitement of the recently announced VL integration with Sightline's Play+ solution, convinced us that acquiring VL made more sense than continuing under a partnership arrangement," said Michael Dominelli, VP Product and Marketing for NRT.  "Ryan McClellan and his team have built a truly amazing product suite.  The VL platform, along with our slot machine and redemption kiosk integrations, and pending merger with Sightline, will allow the combined entity to provide a frictionless payment experience throughout the entire casino ecosystem."

Financing for the VL acquisition was provided by Fifth Third Bank

About NRT & Sightline

On closing, NRT Sightline(TM) is a global leader in the design and development of enterprise platforms for the casino industry. Every year we enable more than 1 billion physical and digital commerce experiences at over 600 casino properties worldwide.  By seamlessly combining technological innovation with strategic partnerships, we create the most convenient, reliable, and secure omni-channel payment ecosystem for casino operators and their guests. NRT Sightline has been recognized with numerous industry awards, including the coveted "Most Innovative Gaming Technology Product of the Year" for our Play+(TM) cloud-based cashless funding platform. Our solutions are used by casinos, lotteries, race and sports, banking & retailers around the world. We operate across 7 countries and have corporate offices in Las Vegas, Toronto, Macau, and Singapore.

For further information about Sightline or its pending merger with NRT, please contact Omer Sattar, Sightline's EVP Strategic Relationships osattar@sightlinepayments.com.

Sightline's Play+ is patent protected by United States Patent Nos. 8,708,809, 8,777,725, 8,998,708, 9,196,123, 9,245,413, 9,251,651, 9,466,176, 9,

715,785, 9, 715,787 and 9,721,430.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NRT Sightline via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum